MX2021012608A - Nuevas moleculas para terapia y diagnostico. - Google Patents
Nuevas moleculas para terapia y diagnostico.Info
- Publication number
- MX2021012608A MX2021012608A MX2021012608A MX2021012608A MX2021012608A MX 2021012608 A MX2021012608 A MX 2021012608A MX 2021012608 A MX2021012608 A MX 2021012608A MX 2021012608 A MX2021012608 A MX 2021012608A MX 2021012608 A MX2021012608 A MX 2021012608A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- synuclein
- dementia
- lewy
- syn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19170207 | 2019-04-18 | ||
| EP19207105 | 2019-11-05 | ||
| EP20165055 | 2020-03-23 | ||
| PCT/EP2020/060898 WO2020212593A1 (en) | 2019-04-18 | 2020-04-17 | Novel molecules for therapy and diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012608A true MX2021012608A (es) | 2021-11-12 |
Family
ID=70285703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012608A MX2021012608A (es) | 2019-04-18 | 2020-04-17 | Nuevas moleculas para terapia y diagnostico. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12534519B2 (https=) |
| EP (1) | EP3956027A1 (https=) |
| JP (1) | JP7689373B2 (https=) |
| KR (1) | KR20210154179A (https=) |
| CN (2) | CN121873233A (https=) |
| AU (1) | AU2020258025A1 (https=) |
| CA (1) | CA3133909A1 (https=) |
| MX (1) | MX2021012608A (https=) |
| TW (1) | TW202104255A (https=) |
| WO (1) | WO2020212593A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| JPWO2022265091A1 (https=) * | 2021-06-18 | 2022-12-22 | ||
| CN113912714B (zh) * | 2021-12-15 | 2022-02-22 | 北京凯祥弘康生物科技有限公司 | 特异性结合α-突触核蛋白的抗体及其应用 |
| CN113912712B (zh) * | 2021-12-15 | 2022-03-08 | 北京凯祥弘康生物科技有限公司 | 抗α-突触核蛋白的单克隆抗体的制备及其应用 |
| KR20240176098A (ko) * | 2023-06-14 | 2024-12-24 | 경상국립대학교산학협력단 | 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물 |
| WO2025093720A1 (en) | 2023-11-02 | 2025-05-08 | Betasense Gmbh | Methods for determining misfolded alpha-synuclein in a sample |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
| WO2025158162A1 (en) * | 2024-01-25 | 2025-07-31 | Imperial College Innovations Limited | Alpha-synuclein antibody |
| CN120064410A (zh) * | 2025-04-28 | 2025-05-30 | 协和生物制药（天津）有限公司 | 一种用于α-突触核蛋白检测的电化学生物传感器 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| DK1069185T3 (da) | 1998-04-03 | 2011-06-27 | Chugai Pharmaceutical Co Ltd | Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| US20050147989A1 (en) * | 2003-10-02 | 2005-07-07 | Uwe Bertsch | Screening assay for aggregations |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| JP6027011B2 (ja) | 2010-10-26 | 2016-11-16 | エーシー イミューン ソシエテ アノニム | 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物 |
| JP6325463B2 (ja) | 2012-03-16 | 2018-05-16 | コヴァジェン アクチェン ゲゼルシャフト | 抗腫瘍活性を有する新規結合分子 |
| GB201512203D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10160800B2 (en) | 2016-06-02 | 2018-12-25 | Medimmune Limited | Antibodies to α-synuclein and uses thereof |
| BR112018014281A2 (pt) * | 2016-11-15 | 2018-12-18 | H Lundbeck As | agentes, usos e métodos para o tratamento da sinucleinopatia |
| EP3555127B1 (en) * | 2016-12-16 | 2024-12-18 | H. Lundbeck A/S | Agents, uses and methods |
| US11155608B2 (en) * | 2017-08-23 | 2021-10-26 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against pathological alpha-synuclein, and methods using same |
-
2020
- 2020-04-17 JP JP2021561633A patent/JP7689373B2/ja active Active
- 2020-04-17 CA CA3133909A patent/CA3133909A1/en active Pending
- 2020-04-17 WO PCT/EP2020/060898 patent/WO2020212593A1/en not_active Ceased
- 2020-04-17 KR KR1020217036474A patent/KR20210154179A/ko active Pending
- 2020-04-17 CN CN202511931795.2A patent/CN121873233A/zh active Pending
- 2020-04-17 US US17/603,513 patent/US12534519B2/en active Active
- 2020-04-17 AU AU2020258025A patent/AU2020258025A1/en active Pending
- 2020-04-17 MX MX2021012608A patent/MX2021012608A/es unknown
- 2020-04-17 CN CN202080044911.8A patent/CN114206444B/zh active Active
- 2020-04-17 EP EP20718677.6A patent/EP3956027A1/en active Pending
- 2020-04-20 TW TW109113222A patent/TW202104255A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7689373B2 (ja) | 2025-06-06 |
| EP3956027A1 (en) | 2022-02-23 |
| TW202104255A (zh) | 2021-02-01 |
| CN114206444A (zh) | 2022-03-18 |
| CN114206444B (zh) | 2026-01-06 |
| CA3133909A1 (en) | 2020-10-22 |
| CN121873233A (zh) | 2026-04-17 |
| AU2020258025A1 (en) | 2021-11-25 |
| JP2022529344A (ja) | 2022-06-21 |
| KR20210154179A (ko) | 2021-12-20 |
| US20220298231A1 (en) | 2022-09-22 |
| US12534519B2 (en) | 2026-01-27 |
| WO2020212593A1 (en) | 2020-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012608A (es) | Nuevas moleculas para terapia y diagnostico. | |
| EP4001277A3 (en) | Bicyclic compounds for diagnosis and therapy | |
| MX2020012932A (es) | Nuevos compuestos para diagnostico. | |
| Pain et al. | Neuroprotective effects of neuropeptide Y against neurodegenerative disease | |
| Li et al. | Electroacupuncture decreases cognitive impairment and promotes neurogenesis in the APP/PS1 transgenic mice | |
| MX2022006676A (es) | Nuevas moleculas para terapia y diagnostico. | |
| MX2011010353A (es) | Composicion farmaceutica. | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
| MY164376A (en) | Phosphospecific antibodies recognizing tau | |
| BR112021023487A2 (pt) | Moléculas de ligação anti-tdp-43 e usos das mesmas | |
| RU2017103446A (ru) | УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ | |
| MX2018000696A (es) | Anticuerpos humanizados anti-beta-amiloide piroglutamados. | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| Bartlett et al. | Neuroendocrine and neurotrophic signaling in Huntington’s disease: implications for pathogenic mechanisms and treatment strategies | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX2023010625A (es) | Anticuerpos anti-beta amiloide y usos de estos. | |
| Jang et al. | Seizure‐Induced Regulations of Amyloid‐β, STEP61, and STEP61 Substrates Involved in Hippocampal Synaptic Plasticity | |
| WO2022093552A3 (en) | Rev-erb agonists | |
| PH12012501882A1 (en) | Humanized antibody against amyloid beta | |
| Chen et al. | Transfer of three transcription factors via a lentiviral vector ameliorates spatial learning and memory impairment in a mouse model of Alzheimer's disease | |
| AR118788A1 (es) | Moléculas para terapia y diagnóstico | |
| MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
| Lam et al. | Sleep disturbances and disorders–A risk factor for cognitive decline and dementia | |
| Atzori et al. | α7 nicotinic acetylcholine receptor-mediated anti-inflammatory actions modulate brain functions |